Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Mar 17, 2019- New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy- Data from a sub-analysis of imaging data provides further clarity regarding which patients benefit most from treatment with MitraClip- On Thursday, MitraClip received FDA approval for new, expanded indication to treat heart failure patients with secondary mitral regurgitation- Mar 14, 2019- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation- Approval is based on groundbreaking pivotal data from the COAPT™ Trial- New indication significantly expands number of people with mitral regurgitation that can be treated with the MitraClip device
- Mar 6, 2019- Five late-breaking data presentations at ACC 2019 showcase the breadth and depth of Abbott's cardiovascular portfolio- New late-breaking data highlight outcomes for key Abbott cardiovascular technologies: MitraClip, HeartMate 3, CardioMEMS and XIENCE
- Mar 5, 2019Regional Medical Laboratory, Inc., which is part of the Ascension network, partners with Abbott, the global health leader, to advance lab capabilities and help improve health outcomes